Zunehmende Luftnot und wechselnde Gelenkbeschwerden

Zusammenfassung

Bei rheumatologischen Erkrankungen soll immer die Möglichkeit einer Lungenmanifestation überprüft werden. Eine interstitielle Lungenerkrankung kann in diesen Fällen häufig letal enden. Im vorgestellten Fall ist der Zusammenhang der progredienten Dyspnoe und der neu aufgetretenen Hautirritationen als besonders wichtig zu sehen. Hier konnte durch eine rasche Therapie mit Immunsuppression und Plasmapherese ein gutes Ergebnis erzielt werden.

Abstract

In rheumatic diseases the possibility of pulmonary manifestation must always be considered and checked. Interstitial lung disease can often be fatal in these cases. In the presented case, the link between progressive dyspnea and newly occurring skin irritation is to be seen as particularly important. A good outcome can be achieved by immediate therapy with immunosuppression and plasmapheresis.

Schlüsselwörter

Dermatomyositis - interstitielle Lungenerkrankung - Plasmapherese - Immunsuppression - MDA5

Keywords

dermatomyositis - interstitial lung disease - plasmapheresis - immunosuppression - MDA5

Publication History

Received: 12 October 2022

Accepted after revision: 18 January 2023

Article published online:
23 March 2023

• Literatur

• 1 Wu W, Guo L, Fu Y. et al. Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis. Clinic Rev Allerg Immunol 2021; 60: 293-304 DOI: 10.1007/s12016-020-08822-5. (PMID: 33405101)
• 2 Qudsiya Z, Waseem M. Dermatomyositis. In: . 2021. Treasure Island (FL): StatPearls Publishing;
• 3 Satoh M, Tanaka S, Ceribelli A. et al. A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy. Clin Rev Allergy Immunol 2017; 52: 1-19 DOI: 10.1007/s12016-015-8510-y. (PMID: 26424665)
• 4 Allenbach Y. et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody. Neurology 2020; 95: e70-e78 DOI: 10.1212/WNL.0000000000009727. (PMID: 32487712)
• 5 Santos-Briz A, Calle A, Linos K. et al. Dermatomyositis panniculitis: a clinicopathological and immunohistochemical study of 18 cases. J Eur Acad Dermatol Venereol 2018; 32: 1352-1359 DOI: 10.1111/jdv.14932.
• 6 Romero-Bueno F, Diaz del Campo P, Trallero-Araguás E. et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Seminars in Arthritis and Rheumatism 2020; 50: 776-790 DOI: 10.1016/j.semarthrit.2020.03.007.
• 7 Abe Y, Kusaoi M, Tada K. et al. Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy. Rheumatology 2020; 59: 767-771 DOI: 10.1093/rheumatology/kez357.
• 8 Fine A, Karp JK, Peedin AR. The role of therapeutic plasma exchange in clinically amyopathic dermatomyositis with MDA-5 antibody: A case report and review of the literature. J Clin Apher 2020; 35: 483-487 DOI: 10.1002/jca.21815. (PMID: 33617011)
• 9 Gono T, Masui K, Sato S. et al. Mortality Risk Stratification Using Cluster Analysis in Patients With Myositis-Associated Interstitial Lung Disease Receiving Initial Triple-Combination Therapy. Front Med (Lausanne) 2022; 9 DOI: 10.3389/fmed.2022.883699. (PMID: 35615085)
• 10 He C, Li W, Xie Q. et al. Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review. Front Immunol 2022; 12 DOI: 10.3389/fimmu.2021.820163.